Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRIDGE-T: addressing temporal unreliability in federated learning for edge-enabled IoT networks.

Scientific reports·2026
Same author

Tobacco cessation intervention for individuals with severe mental illness in Bangladesh, India, and Pakistan: protocol for a multi-country feasibility randomised controlled trial (SCIMITAR-SA).

Contemporary clinical trials communications·2026
Same author

Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.

The Cochrane database of systematic reviews·2025
Same author

Engineering TAG-72 and CD30 CAR-T Cells for T Cell Malignancies.

Immunological investigations·2025
Same author

CRISPR-Cas9 knockout of DGKα/ζ improves the anti-tumor activities of TAG-72 CAR-T cells in ovarian cancer.

Molecular therapy. Oncology·2025
Same author

Atypical presentation of primary lung abscess in an infant.

Pediatric pulmonology·2024
Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026
Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026
Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026
Same journal

PACAP and Maxadilan (PAC1 Agonist) Influence Plaque Progression, Migratory Ability, and Mitochondrial Morphology and Dynamics in Vascular Smooth Muscle Cells.

Cells·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

730

CAR-NK Engineering to Overcome TME Barriers.

Fahmida Islam1,2, Aleta Pupovac1,2, Richard L Boyd1,2

  • 1Cartherics Pty Ltd., Notting Hill, VIC 3168, Australia.

Cells
|January 9, 2026
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor (CAR)-natural killer (NK) cell therapy shows promise for solid tumors, overcoming challenges like the immunosuppressive tumor microenvironment (TME). Strategies and complementary therapies are key for effective CAR-NK cancer treatment.

Keywords:
CAR-NK cellsTMEantigen heterogeneityimmune escape

More Related Videos

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
08:29

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

1.3K
Engineering Platform and Experimental Protocol for Design and Evaluation of a Neurally-controlled Powered Transfemoral Prosthesis
11:16

Engineering Platform and Experimental Protocol for Design and Evaluation of a Neurally-controlled Powered Transfemoral Prosthesis

Published on: July 22, 2014

16.6K

Related Experiment Videos

Last Updated: Jan 13, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

730
Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
08:29

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

1.3K
Engineering Platform and Experimental Protocol for Design and Evaluation of a Neurally-controlled Powered Transfemoral Prosthesis
11:16

Engineering Platform and Experimental Protocol for Design and Evaluation of a Neurally-controlled Powered Transfemoral Prosthesis

Published on: July 22, 2014

16.6K

Area of Science:

  • Immunology
  • Cancer Therapy
  • Cellular Engineering

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy is effective for hematological cancers but limited by toxicity and allogeneic incompatibility.
  • CAR-natural killer (NK) cells offer an alternative with inherent anti-tumor functions and potential for off-the-shelf allogeneic use.
  • CAR-NK efficacy against solid tumors is hindered by the immunosuppressive tumor microenvironment (TME) and tumor-specific challenges.

Purpose of the Study:

  • To review the challenges hindering CAR-NK cell therapy in solid tumors.
  • To outline strategies to overcome these barriers and enhance CAR-NK cell efficacy.
  • To highlight the potential of combining CAR-NK cells with other immunotherapies and advanced technologies.

Main Methods:

  • Literature review of current CAR-NK therapy research for solid tumors.
  • Analysis of barriers including TME characteristics, tumor antigen heterogeneity, and immune escape mechanisms.
  • Exploration of combination strategies with other immunotherapies and novel technologies.

Main Results:

  • Solid tumors present significant barriers to CAR-NK cells, including immunosuppressive TME, antigen heterogeneity, immune escape, and impaired cell function.
  • CAR-NK cell limitations include fratricide, metabolic and structural barriers within the TME, and issues with homing and persistence.
  • Combination therapies and advanced technologies are crucial for enhancing CAR-NK cell effectiveness.

Conclusions:

  • CAR-NK cell therapy faces substantial hurdles in solid tumor treatment due to the complex TME and tumor-specific factors.
  • Overcoming these challenges requires innovative strategies, including combination immunotherapy and advanced technological approaches.
  • Further research and technological advancements are essential for the successful clinical translation of CAR-NK therapy for solid tumors.